Literature DB >> 21376776

Xenobiotic metabolism and disposition in human lung: transcript profiling in non-tumoral and tumoral tissues.

Julie Leclerc1, Elisabeth Courcot-Ngoubo Ngangue, Christelle Cauffiez, Delphine Allorge, Nicolas Pottier, Jean-Jacques Lafitte, Michel Debaert, Sophie Jaillard, Franck Broly, Jean-Marc Lo-Guidice.   

Abstract

The lung is directly exposed to a wide variety of inhaled toxicants and carcinogens. In order to improve our knowledge of the cellular processing of these compounds in the respiratory tract, we investigated the mRNA expression level of 380 genes encoding xenobiotic-metabolizing enzymes (XME), transporters, nuclear receptors and transcription factors, in pulmonary parenchyma (PP), bronchial mucosa (BM) and tumoral lung tissues from 12 patients with non-small cell lung cancer (NSCLC). Using a high throughput quantitative real-time RT-PCR method, we found that ADH1B, CYP4B1, CES1 and GSTP1 are the major XME genes expressed both in BM and PP. Our results also documented the predominant role played by the xenosensor AhR in human lung. The gene expression profiles were different for BM and PP, with a tendency toward increased mRNA levels of phase I and phase II XME genes in BM, suggesting major differences in the initial stages of xenobiotic metabolism. Some of the significantly overexpressed genes in BM (i.e. CYP2F1, CYP2A13, CYP2W1, NQO1…) encode proteins involved in the bioactivation of procarcinogens, pointing out distinct susceptibility to xenobiotics and their toxic effects between these two tissue types. Additionally, interindividual differences in transcript levels observed for some genes may be of genetic origin and may contribute to the variability in response to environmental exposure and, consequently, in the risk of developing lung diseases. A global decrease in gene expression was observed in tumoral specimens. Some of the proteins are involved in the metabolism or transport of anti-cancer drugs and their influence in the response of tumors to chemotherapy should be considered. In conclusion, the present study provides an overview of the cellular response to toxicants and drugs in healthy and cancerous human lung tissues, and thus improves our understanding of the mechanisms of chemical carcinogenesis as well as cellular resistance to chemotherapy.
Copyright © 2011 Elsevier Masson SAS. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21376776     DOI: 10.1016/j.biochi.2011.02.012

Source DB:  PubMed          Journal:  Biochimie        ISSN: 0300-9084            Impact factor:   4.079


  12 in total

1.  Targeted versus chrono-targeted chemotherapy for inhaled chemotherapy in non-small cell lung cancer.

Authors:  Paul Zarogoulidis; Kaid Darwiche; George Kalamaras; Haidong Huang; Wolfgang Hohenforst-Schmidt; Konstantinos Zarogoulidis
Journal:  Transl Lung Cancer Res       Date:  2013-02

Review 2.  Small Airway Susceptibility to Chemical and Particle Injury.

Authors:  Leonie Francina Hendrina Fransen; Martin Oliver Leonard
Journal:  Respiration       Date:  2021-10-14       Impact factor: 3.966

Review 3.  Targeting inhaled therapy beyond the lungs.

Authors:  Ninell P Mortensen; Anthony J Hickey
Journal:  Respiration       Date:  2014       Impact factor: 3.966

4.  Gene expression analysis of membrane transporters and drug-metabolizing enzymes in the lung of healthy and COPD subjects.

Authors:  Tove Berg; Tove Hegelund Myrbäck; Marita Olsson; Janeric Seidegård; Viktoria Werkström; Xiao-Hong Zhou; Johan Grunewald; Lena Gustavsson; Magnus Nord
Journal:  Pharmacol Res Perspect       Date:  2014-06-12

5.  Tumoral expression of drug and xenobiotic metabolizing enzymes in breast cancer patients of different ethnicities with implications to personalized medicine.

Authors:  Yan Li; Albert Steppi; Yidong Zhou; Feng Mao; Philip Craig Miller; Max M He; Tingting Zhao; Qiang Sun; Jinfeng Zhang
Journal:  Sci Rep       Date:  2017-07-06       Impact factor: 4.379

6.  Xenobiotic metabolism in differentiated human bronchial epithelial cells.

Authors:  Jan J W A Boei; Sylvia Vermeulen; Binie Klein; Pieter S Hiemstra; Renate M Verhoosel; Danyel G J Jennen; Agustin Lahoz; Hans Gmuender; Harry Vrieling
Journal:  Arch Toxicol       Date:  2016-10-13       Impact factor: 5.153

7.  Expression of MATE1, P-gp, OCTN1 and OCTN2, in epithelial and immune cells in the lung of COPD and healthy individuals.

Authors:  Tove Berg; Tove Hegelund-Myrbäck; Johan Öckinger; Xiao-Hong Zhou; Marie Brännström; Michael Hagemann-Jensen; Viktoria Werkström; Janeric Seidegård; Johan Grunewald; Magnus Nord; Lena Gustavsson
Journal:  Respir Res       Date:  2018-04-20

8.  HapMap-based study: CYP2A13 may be a potential key metabolic enzyme gene in the carcinogenesis of lung cancer in non-smokers.

Authors:  Feng Hua; Yonglu Guo; Qiang Sun; Leizhou Yang; Fang Gao
Journal:  Thorac Cancer       Date:  2019-02-26       Impact factor: 3.500

Review 9.  Vectors for inhaled gene therapy in lung cancer. Application for nano oncology and safety of bio nanotechnology.

Authors:  Paul Zarogouldis; Nikos K Karamanos; Konstantinos Porpodis; Kalliopi Domvri; Haidong Huang; Wolfgang Hohenforst-Schimdt; Eugene P Goldberg; Konstantinos Zarogoulidis
Journal:  Int J Mol Sci       Date:  2012-08-29       Impact factor: 6.208

Review 10.  Current status and future perspectives of mass spectrometry imaging.

Authors:  Surendra Nimesh; Susantha Mohottalage; Renaud Vincent; Prem Kumarathasan
Journal:  Int J Mol Sci       Date:  2013-05-28       Impact factor: 5.923

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.